Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

BACKGROUND: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Angelo, Fabbrocicni, Gabriella, Cacciapuoti, Sara, Potestio, Luca, Gallo, Lucia, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983574/
https://www.ncbi.nlm.nih.gov/pubmed/36873660
http://dx.doi.org/10.2147/CCID.S402183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983574/
https://www.ncbi.nlm.nih.gov/pubmed/36873660
http://dx.doi.org/10.2147/CCID.S402183

Ejemplares similares